Point: Incident Exposures, Prevalent Exposures, and Causal Inference: Does Limiting Studies to Persons Who Are Followed from First Exposure Onward Damage Epidemiology?

American Journal of Epidemiology

Volumn 182, Issue 10, 2015, Pages 826-833

  Vandenbroucke, Jan ^a   Pearce, Neil ^b,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c MASSEY UNIVERSITY   (New Zealand)

Author keywords

dynamic populations; epidemiologic methods; incidence rate; incident exposure; left truncation; prevalent exposure; right censoring; study design

Indexed keywords

COHORT ANALYSIS; DATA ASSIMILATION; DISEASE INCIDENCE; DISEASE PREVALENCE; DISEASE TRANSMISSION; DISEASE TREATMENT; EPIDEMIOLOGY; EXPERIMENTAL DESIGN; STUDY METHOD;

ADVERSE OUTCOME; ANALYSIS; ARTICLE; CAUSAL INFERENCE; EPIDEMIOLOGICAL DATA; EPIDEMIOLOGY; FIRST EXPOSURE PRINCIPLE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; POPULATION; POPULATION DYNAMICS; POPULATION EXPOSURE; PREVALENCE; STATISTICAL ANALYSIS; STATISTICAL BIAS; STATISTICAL PARAMETERS; STUDY DESIGN; THEORY; CAUSALITY; DRUG COMBINATION; ESTROGEN THERAPY; FEMALE; HEALTH SURVEY; LIFE TABLE; METHODOLOGY; MYOCARDIAL INFARCTION; PROCEDURES; PROPORTIONAL HAZARDS MODEL; TIME FACTOR;

DRUG COMBINATION; ESTROGEN; GESTAGEN;

BIAS (EPIDEMIOLOGY); CAUSALITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG COMBINATIONS; EPIDEMIOLOGIC METHODS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; INCIDENCE; LIFE TABLES; MYOCARDIAL INFARCTION; PREVALENCE; PROGESTINS; PROPORTIONAL HAZARDS MODELS; PUBLIC HEALTH SURVEILLANCE; RESEARCH DESIGN; TIME FACTORS;

EID: 84947554355     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwv225     Document Type: Article

References (51)

1. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920.
2. Hernán MA. The hazards of hazard ratios. Epidemiology. 2010;21(1):13-15.
3. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf. 2010;19(8):858-868.
4. Johnson ES, Bartman BA, Briesacher BA, et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013;22(1):1-6.
5. Schisterman EF, Cole SR, Ye A, et al. Accuracy loss due to selection bias in cohort studies with left truncation. Paediatr Perinat Epidemiol. 2013;27(5):491-502.
6. Institute of Medicine. Ethical and Scientific Issues in Studying the Safety of Approved Drugs. Washington, DC: The National Academies Press; 2012.
7. Hernán MA, Hernández-Di´az S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(5):615-625.
8. Vandenbroucke JP, Pearce N. Incidence rates in dynamic populations. Int J Epidemiol. 2012;41(5):1472-1479.
9. Vandenbroucke JP, Pearce N. Case-control studies: basic concepts. Int J Epidemiol. 2012;41(5):1480-1489.
10. Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. J Educ Psychol. 1974;66(5):688-701.
11. Robins JM. The analysis of randomized and non-randomized AIDS treatment trials using a new approach to causal inference in longitudinal studies. In: Sechrest L, Freeman L, Mulley A, eds. Health Services Research Methodology: a Focus on AIDS. Bethesda, MD: US Public Health Service, National Center for Health Services Research; 1989:113-159.
12. Hernán MA. With great data comes great responsibility: publishing comparative effectiveness research in epidemiology. Epidemiology. 2011;22(3):290-291.
13. Hernán MA, Taubman SL. Does obesity shorten life? The importance of well-defined interventions to answer causal questions. Int J Obes (Lond). 2008;32(suppl 3):S8-S14.
14. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58(5):295-300.
15. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008.
16. Devroede GJ, Taylor WF, Sauer WG, et al. Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med. 1971;285(1):17-21.
17. Kurtzke JF. On estimating survival; a tale of two censors. J Clin Epidemiol. 1989;42(2):169-175.
18. Goldner J, Wisnant JP, Taylor WF. Long-term prognosis of transient cerebral ischemic attacks. Stroke. 1971;2(2):160-167.
19. Checkoway H, Pearce N, Kriebel D. Research Methods in Occupational Epidemiology. 2nd ed. New York, NY: Oxford University Press; 2004.
20. Cleves M. An Introduction to Survival Analysis Using Stata. 2nd ed. College Station, TX: Stata Press; 2008.
21. Lamarca R, Alonso J, Gómez G, et al. Left-truncated data with age as time scale: an alternative for survival analysis in the elderly population. J Gerontol A Biol Sci Med Sci. 1998;53(5):M337-M343.
22. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 2000;160(1):49-52.
23. Kemmeren JM, Algra A, Meijers JC, et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood. 2004;103(3):927-933.
24. Kemmeren JM, Algra A, Meijers JC, et al. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thromb Haemost. 2002;87(2):199-205.
25. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144-153.
26. McEvoy SP, Stevenson MR, McCartt AT, et al. Role of mobile phones in motor vehicle crashes resulting in hospital attendance: a case-crossover study. BMJ. 2005;331(7514):428.
27. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med. 2003;348(7):645-650.
28. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol. 2005;162(5):404-414.
29. Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766-779.
30. Beral V, Reeves G, Bull D, et al. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011;103(4):296-305.
31. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
32. Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol. 2008;167(10):1207-1216.
33. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573-1580.
34. Sweetland S, Beral V, Balkwill A, et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10(11):2277-2286.
35. Vandenbroucke JP. The HRT controversy: observational studies and RCTs fall in line. Lancet. 2009;373(9671):1233-1235.
36. Prentice RL. Data analysis methods and the reliability of analytic epidemiologic research. Epidemiology. 2008;19(6):785-788; discussion 789-793.
37. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet. 2004;363(9422):1728-1731.
38. Schneeweiss S, Patrick AR, Stürmer T, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007;45(10 suppl 2):S131-S142.
39. Danaei G, Rodríguez LA, Cantero OF, et al. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res. 2013;22(1):70-96.
40. Danaei G, Tavakkoli M, Hernán MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012;175(4):250-262.
41. Brenner H, Hakulinen T. Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol. 2002;20(3):826-832.
42. Turnbull BW. Nonparametric estimation of a survivorship function with doubly censored data. J Am Stat Assoc. 1974;69(345):169-173.
43. Turnbull BW. The empirical distribution function with arbitrarily grouped, censored and truncated data. J R Stat Soc Ser B Stat Methodol. 1976;38(3):290-295.
44. Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280(17):1497-1503.
45. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. 2006;166(3):357-365.
46. Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009;2(3):155-163.
47. Doll R, Hill AB. The mortality of doctors in relation to their smoking habits; a preliminary report. Br Med J. 1954;1(4877):1451-1455.
48. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004;328(7455):1519.
49. Preston DL, Ron E, Tokuoka S, et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res. 2007;168(1):1-64.
50. Franklin JG, Paus MD, Pluetschow A, et al. Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Cochrane Database Syst Rev. 2005;(4):CD003187.
51. van Eggermond AM, Schaapveld M, Lugtenburg PJ, et al. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma. Blood. 2014;124(3):319-327; quiz 466.